BRKR - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the Bruker’s Third Quarter 2019 Earnings Conference Call. I’d now like to turn the conference call over to Miroslava Minkova. Please go ahead, ma’am.

Miroslava Minkova

Good afternoon. I would like to welcome everyone to Bruker’s third quarter 2019 earnings conference call. Minkova, Investor Miroslava Development. and is name Director Relations of Corporate My

me Frank Herman, and Officer. are today’s our our Financial Joining call CEO; Laukien, on President and Chief Gerald

during release slide Relations a The website. Bruker’s the PDF can issued earnings Quarterly be presentation presentation. the this downloaded to call, we’ll addition earlier In Investor today, be today’s of Results conference referencing on we from section

non-GAAP included financial GAAP today’s our information. of During be call, is to are will our website which financial release, highlighting measures our at in we earnings non-GAAP on Reconciliations posted ir.bruker.com.

begin, like I Before Bruker’s we on would Safe shown Harbor statement reference X. Slide to

and the to, During the company’s projections statements as not the events such and in described differ are and results call, we today’s of statements. but filings, of on risk conference subsequent our include, financial Factors available may the regarding release are that website. our uncertainties. and differences which will that on company be cause website discussed those as actual materially involve The such in in future and in this Form making SEC’s from limited the forward-looking performance might earnings well XX-K course operational

statements our today. quarter or full in XXXX. not new any not February that other do of and these rely should intend reasons the following results current prior to XXXX. future to as XX, financial note subsequent our views or year as information, related of October Therefore, XXXX our events representing we business is update to to as of forward-looking statements to and Also the information conditions prior today, outlook outlook our on based date release you our fourth Consistent practice, forward-looking with on

a of Gerald third We detail. business today’s then in the financials providing the XXXX Frank will will quarter for cover summary. more call with begin

over Now, Bruker’s Laukien. Frank call CEO, I’d like to to turn the

Frank Laukien

today’s thank call. very and of us strong increases. you third Bruker quarter with everyone for on XXXX a good joining EPS afternoon Good Miroslava. Thanks, delivered and revenue

revenue currency our X.X% quarter, was third constant was growth XX% year-over-year and the growth During organic year-over-year. revenue

On a XX% the third of bottom increase quarter EPS compared the XXXX. non-GAAP of reported line, to $X.XX, we

comparison XXXX. performance We are against challenging pleased our QX of with strong a in very

this at made our margin Meeting HUPO September growth, diaPASEF initiative, further During reporting we protein the quarter, Accelerate at the workflow and third in Conference high with the timsTOF Project gigahertz August. EUROISMAR progress data first launching up Pro high NMR X.X for important in

of on NMR Project class we slow structural this our faced Accelerate, down metrology, the gigahertz for shipped X.X very QX overall, an first cyclical our recorded we customer and in X.X ever with We gigahertz gigahertz additional revenue Within and class XXXX gigahertz NMR in NMR year. to we progress NMR have a a proteomics, are accepted in microbiology while this semiconductor biology. second especially year, encouraged

segments segment, on Turning comprised $XXX.X growth Instruments and increased XXXX, X.X% Intercompany specifics our third a Slide increased on X, Revenue Eliminations. million quarter net of to an basis. X.X% in at our year-over-year at to Bruker’s of year-over-year, organic of decline organic XX.X% X.X% minus revenue BEST Scientific the

currency During foreign a X.X%. while revenue growth, XX% was X.X% headwind the acquisitions basis, translation a of to quarter, third currency On added minus increased constant revenue year-over-year. our

increased XXXX bps third XXX year-over-year. Our gross margin non-GAAP quarter

$X.XX in XX.X% $X.XX per foreign diluted bps and compared non-GAAP GAAP reported to On In driven compared year-over-year, of to impact XXXX XXXX, Our by rates. of XXXX. basis, QX EPS QX of $X.XX of XXXX XX share currency from primarily a of quarter QX operating was $X.XX favorable per increased margin non-GAAP QX improved EPS in share Bruker third XXXX.

so XXXX, compared anticipated recall, had to be non-GAAP flat with we EPS relatively quarter may pleased XXXX would results. third that third you we a are quarter As these strong

I XXXX. of On Bruker’s for Slide months X, performance nine first the show

million revenue months growth year-to-date the of first X% compared X.X% year-over-year comprised XXXX a in X.X% our Organic was Instruments million, nine and to nine Intercompany net is months of in increase $XXX to of revenue the Eliminations. $X,XXX.X growth increased organic segments first in X% growth by BEST Scientific segment, the Our organic of XXXX.

market XX% XXXX. Acquisitions and basis, XXXX, and metrology remained headwind first X.X% of constant biopharma in added has months year exchange microbiology industrial months End months the we applied nine Semiconductor markets X% growth the nine first of delivered a foreign favorable the to while our markets year-over-year Bruker’s growth top has On government, currency minus conditions nine line weak. in year-over-year. and of the slowed. first quite revenue academic while remained for was of in the demand

For segment segment the we orders call. were BEST first will up in organic months Scientific order later the superconductor single due bookings for of that digits, discuss renewed to supply were our agreements XXXX, long-term mid the in whereas our Instruments strongly up

XXX in gross reported non-GAAP compared – months XX changes same the first acquisitions operating period in the $X.XX of On EPS months margin points XXXX. XXXX, in of and an basis GAAP operational points rates. XXXX nine misspoke margin increased basis the – we tailwind XX to a accretive Non-GAAP approximate foreign basis, improvements, I as Our year. from points approximate expanded from of nine XXX $X.XX to last in bps period same first currency the compared Bruker in benefited

the $X.XX, in year-over-year. EPS an of of quarters increase three non-GAAP XXXX XX.X% first was our Finally,

instruments, first our our nine BEST X comparison of months and XXXX Slide further the to highlights three I in months in to X provide scientific where on XXXX. now, the all constant in currency of segment turn Please and performance of the nine groups and of first

this the dollar mid-single small aftermarket, third of quarter Group – due as to acquisitions. quarter in however old both, system BioSpin year-to-date revenue This increased gigahertz revenue. BioSpin’s pricing legacy million. third include revenue order. revenue to modest and in $XXX software The growth Year-to-date as in from constant XXXX second system digits were systems of in our the contribution recognition two margin X.X NMR a well results on an for revenue currency reflected contributions systems XXXX with and

BioSpin systems in higher revenue grow year period the first imaging revenues at good and of in aftermarket the we full grew for expect digits revenue to preclinical nine slightly a months overall, or compared in BioSpin the to year XXXX. the BioSpin’s XXXX. organically pace same Group our year mid-single fiscal were

in performance mass our CALID detection a including $XXX Within XXXX in organically. also in both our of a Group first months nine on the million solutions in very proteomics. of first high-teens double-digit MALDI currency FTIR/NIR Biotyper see business, Moving our to revenues to business grew majority we CALID, pace acquisition. with the molecular revenue continue strong to strong includes XXXX CALID well life in science Bruker-Hain CBRNE months as nine our which at timsTOF in based constant Group. flat. had up now Year-to-date the which business, in includes remains spectrometry spectroscopy, revenue our performance about microbiology, CALID CALID

turn to X. Slide Please

group and reflects in NANO were Bruker of currency up RAVE. revenues compared up Growth constant including NANO Anasys, low-single and organic Now, Alicona digits first prior million were JPK the acquisitions revenues to XXXX. year-over-year. high-teens contributions year-to-date On an the of basis, primarily year in to months nine year-over-year $XXX

seen and industrial have semiconductor metrology some markets. of We signs NANO’s weakening in of demand

from customers. advanced NANO’s nine of first x-ray academic XXXX, solid months grew business the with In demand

tools surface acquisition. year-to-date increased Year-to-date due Our metrology to business revenue NANO higher to year-over-year revenues RAVE tools year-to-date while analysis organically acquisitions. grew our semiconductor due were NANO the

be revenue we full However, our XXXX, year to year-over-year. metrology expect for down semicon digit organically the double

revenue. Bruker’s a metrology X% As business our reminder, for of semi approximately accounts

the was in Moving on up single BEST. the first to months of nine digits BEST revenue mid year-over-year. XXXX,

that MRI led order agreements a backlog Please increase to third updated finalized the a which in than off BEST five-year major two longer delivered more companies, long-term over of quarter, note $XXX that are expected timeline. During BEST be are or supply these to than reported million. renewals orders with

Moving cancer. X.X our ever research X.X gigahertz our proteins At generated as Berlin, in diseases August NMR on with on with and NMR Alzheimer’s, to data factory conference gigahertz data Slide together showed Parkinson’s, a collaborators, X. we first Swiss the at such have generated the we associated EUROISMAR

BioSpin expect XXXX in to gigahertz We to growth X.X begin our that beyond. NMR contribute and will revenue

X. progress the our with excellence operational Turning program. to highlight I Slide

assembled have tested and million and lower is Bruker expected facility been Bruker generated new to engineering than already of a costs and We local on This in tax NANO costs, final we have expect subassembly in production. sensor regional that assembly third test Penang, operational. lower are working more We Penang system from Penang. by final party being products to XXXX, lower NANO and have be is access now which to $XX and now revenue several Malaysia, rates,

cycles our initiatives our third a quarter the We our So, nine further in our well I’m of that Accelerate the us macroenvironment. perform pleased to and Project operational summary, product weaker months position progress believe high-margin high-growth, XXXX. despite progress during to focus with continue excellence with and first sustained innovative

review Let me year-to-date XXXX Gerald over QX Gerald? to will detail. turn our more now our performance who the Herman, and CFO, financial call in

Gerald Herman

today XX.X% XX XXXX XX.X% XXXX. growth of Frank. revenue EPS you. join to quarter XXXX, third reflects quarter quarter you reported basis on $X.XX, $X.XX Thank Bruker’s to non-GAAP in XXXX I’m review We increase $X.XX On pleased QX and highlights of the EPS to compared of from $X.XX of XXXX. million increased in Slide. of $XXX.X starting X.X%. reported GAAP QX which third an financial the in Bruker’s organic was revenue a third

basis the XXXX primarily change non-GAAP while favorable non-GAAP foreign our operating to by XX QX XX.X%, in up XXXX QX with compared translation. exchange profit increased points margin, XXXX operating was driven margin QX

compared for – August XXXX to is our revenue in helps year. when derisk our in QX QX performance for as the shared it better which were our we expected largest fourth our we’re was quarter, and which operational than quarter These when expectations results strong to with we QX pleased a

million in items. shipments timing offset to flow the reflecting partially in $XX was higher $XX the quarter QX and income and to million, prior net XXXX, third of cash expenditures capital XXXX year, of year-over-year relative by Free compared other

increased we XX, debt buildup receivables ended September higher deployed dividends. $XXX quarters repurchases in of and three the capital a expenditures, share inventory shipments our we and XXXX in recent working due with of balances past We XXXX, over later the quarter. growth, QX position on reflecting net capital million revenue as cash As acquisitions were acquisitions,

in a growth from revenue included in another a BSI quarter. perspective year-over-year, third offset headwind currency system low growth by saw gigahertz BioSpin. quarter QX X.X was QX foreign Slide XX we at We BSI which had was earlier, X.X% from shows revenue as decline BEST. at with X.X% noted growth for and acquisitions X.X% bridge organic growth revenue X.X%, X.X%. XXXX. the in This revenue at organic of growth partially of single-digit the From XXXX revenue NMR

revenue as However, this modest Frank the earlier. to mentioned system carried legacy relatively pricing margins and due

low CALID science Our divisions. the quarter all was in group group in basis. quarter, and strong growth on microbiology. in in spectrometry posted teens NANO’s included and third mass life driven NANO organic the This organic high solutions digits single in an up performance by growth

environment equipment, year. this not However, given and into the to weekend growth of quarter group continue for research we level do the metrology the anticipate fourth NANO industrial semiconductor of

perspective, high revenue QX geographic digits single a Europe. From in up was organic

Asia-Pacific growth increased Latin The we and had declined China. of quarter-to-quarter America which other World including to mid-teens single-digit organic good in revenue growth results. revenue high fluctuations. Japan attribute than slightly North primarily the in Rest organically, America strong

currency to gross results. acquisitions increased profit leverage Slide and improvements accretion the rather in from basis QX increase by Group margin CALID points XXX driven favorable of operational from primarily XX rates. shows Non-GAAP changes was in XX.X% our foreign volume and XXXX. our XX.X% non-GAAP in QX XXXX

over XX.X% QX prior in currency and XX business QX XXXX XXXX operating over increased year improvement XXXX. recent translation the XXXX accretive acquisitions. points acquisitions. our related expenses of the margins basis investments in XX.X% by the operating and QX our was driven expenses in to foreign non-GAAP reflecting favorable increased reported

QX this XX.X% compared principally For was XXXX. favorable the in QX third jurisdictional more modest XXXX. driven quarter to of was XX.X%, rate effective in XXXX, by decline tax our non-GAAP mix

$XX approximately the shares third million, quarter third one million. XXXX. QX from average million shares Year-to-date shares we currently million. buyback XX, total which repurchased a of authorization, for million outstanding diluted place were $XXX under through have is shares share remaining in September XXXX. a million total mid-May shares the additional Weighted million quarter, an of down of X.X X.X through total repurchases We our cost $XXX in XXX.X during at

XXXX non-GAAP EPS revenue by finally, year-over-year, growth increased of driven $X.XX QX higher and margins. our XX.X% primarily

X.X% growth foreign revenue of Year-to-date from of Slide first X%, increase CALID, reflects and mid-single BSI X.X%. or revenue XX over X% for a organic of in $XXX shows growth NANO. a double-digit the digit digit million of BioSpin XXXX. year-over-year XXXX this currency with reflecting organic X.X% the is growth XXXX nine our contributions bridge headwind at and up at months acquisitions growth a at low-single year-to-date

eliminations. grew BEST Our X% intercompany segment an on of basis net organic

on of months digits, and Geographically XXXX. double-digits was the revenue basis an XXXX and mid-single organic Asia organic the Bruker’s Pacific months strong up modestly to of revenue grew grew revenue nine growth American first nine European basis, in driven by in first on an compared China. Japan in North

Year-to-date rate, line and investments. operating in our our improvement non-GAAP XX.X%, from from accretion at CALID, to of expenses basis first margin increased with selected XXXX. translation increased XX, XXXX XXXX the acquisitions relative growth foreign points. profit months including drove On Operational revenue roughly gross year-to-date Slide expenses with acquisitions the combined XXX of improvements nine favorable currency

All in, points. first non-GAAP basis XXXX year benefiting the the was margin prior well in acquisitions, of as operational exchange foreign accretion approximately XXX the XX operating from period, in improvement as of CALID, from months tailwind point basis nine our over XX.X%, improvements

year, year-to-date was discrete rate tax of last and rate XX.X% Our lower the driven mix. tax in period revenue of the favorable than effective certain XXXX same items primarily XX.X% by non-GAAP the

grew to accretion nine the a Finally, non-GAAP lower $X.XX relative acquisitions our XXXX, growth, year-over-year. of solid higher months rate XX.X% and revenue of EPS slightly reflecting from margins, tax first

the $XX.X cash was the in $XX.X XXXX capital The months the first weaker free timing XXXX period gigahertz-class by Free XX. million in our our primarily of was shipments. into year-to-date same build-up to product Slide to transitions expenditures driven compared of XXXX. in million, generation in Malaysia and cash factory of production, inventory Turning for for Penang, increases and flow nine NMR

and of the compared XXXX an in cash Our offset days increase of XXX the QX end to lengthened, DPO. at conversion QX in of DIO days cycle to partially XXX by increase an due end at XXXX, DSO,

Turning XXXX now the for full year to XX. guidance Slide on

of elements translation XXXX outlook the our stronger contribution growth acquisitions, updating headwinds. from currency by We’re revenue for offset foreign higher

Given we non-GAAP the full are range year. our raising expected for EPS performance, year-to-date our

and continue expect X%, to to continues X.X%. revenue growth revenue we revenue, XXXX For X.X% X% this between include overall and growth between organic

we revenue, August. spoke about Our to X.X% to acquisitions are expected in now to better than X.X% when you contribute about early reported last

a X%, guidance in to revenue early is translation exchange than X.X% X.X% XX%, compared now equates XX.X%. headwind This constant more between approximately Foreign to now prior our unfavorable projected constant be August. of currency revenue to higher currency growth for XX% growth to and between

sensitive also our point the macro guidance usual we a to order some wider uncertain reflect strong the bit at quarter. macroeconomic businesses. and our into backlog our year-to-date heading than held revenue in in more organic range face fourth more year this But the We now performance of environment

the XX XXXX. translation. XX.X% This from now tailwind We points from an and margin approximately points basis continue basis achieved between to currency foreign level point expected basis expect includes non-GAAP XX to operating XXX improve in

We non-GAAP fully expect year of fully effective full continue diluted million diluted approximately XXX XXXX count and – to of rate tax we XX%, now shares. above share a lower expect

increase increase is from $X.XX and EPS our performance, would in guidance an assumptions $X.XX of expect now year-to-date non-GAAP with which to listed foreign guidance This our represent between slide. rates this XX.X% full an Given currency range which are to we year-over-year. on EPS XX.X% Other along XXXX year of was updated prior non-GAAP a $X.XX. $X.XX,

XXXX financial remained XXXX in made strong nine financial XX.X%. QX with full wrap you objectives progress good growth non-GAAP year year. revenues look to the February. our We the XXXX, to We've EPS reported for first and in up, To and committed forward our months on delivered of and in call performance conference XX.X% of QX Bruker again up updating early full

you to with very I'd much. Miroslava like session. Thank And the call that, the to turn to Q&A over start

Miroslava Minkova

we session. Operator, Gerald. to your In to to Thank to join one begin a participation, please and you, questions follow-up. limit analyst allow would order Q&A like

Operator

of Thank go from our Please question you. And first Couillard ahead. [Operator Brandon come Jefferies. will Instructions]

Brandon Couillard

could year, need your out to of growth you Thanks. where kind hit the next current backdrop. sort quarter? afternoon. you the get to Good to just new of better Is As view deteriorated at Thanks. Frank, relative look you the laid to does you in sat industrial that – you clarify your to second organic X% the you as of if Day? for could it X% help target, out Analyst

Frank Laukien

under necessarily quarter once but another observe February, that else not that, belt today. I’m No, saying have and we're guidance giving do in fourth what our not we everybody doing. Brandon, also obviously We'll is XXXX

– little SEMI. get the for industrial us, part not also recovering But and bit SEMI I here a up of it's in before maybe weaker isn't started our the a than booming. So getting comes other in and of don't but small bad, not fact sun organically it's business rest

think I as it's So expected. about

Brandon Couillard

and just is Then that alluded the all XXX of you that period million kind on should year incremental assume ratably five BEST the contract, over captured to? has of we follow-up a

Frank Laukien

not a and capacity incremental become we planning of basically have stability in because had bit, multi-year contracts this incremental. provides volume before, it's and planning, but not some four it's companies, MRI them with really No, so these companies little larger annual major

healthy On the baseline other hand, very it for business. our sets a best

for it's So, well for not I as really the their but this MRI BEST, incremental. a as think OEM, development entire is very industry customers, good

or ratably question, to But assumption as more years. of that Brandon, control that roughly, first bit a because And yes, a five exactly is part very is good well. your readably not that’s little the customers latter over it the

Brandon Couillard

Super, thank you.

Frank Laukien

long-term well in they have that locked them. but in development, positive business this supply with this not do but to And have and we therefore is we baseline some as incremental. that can we locked a them, business also Very other

Operator

SVB question our Puneet And Please next Souda will from come ahead. Leerink. of go

Puneet Souda

the and question for Thanks the congrats quarter. on

the weak at quarter are sort to about Project timsTOF, mean, is about I just a of microbiology, X% get mean backdrop. one comments this next your the bit stronger And I I growth you're the I you year first easier, you. comparables, just long-term macro quarter a appreciate a much the Accelerate, drivers we industrial organic, So year-over-year of look guiding are want on and But, for number the full those for – a midpoint, quarter-over-quarter, have if sense CALID, guide is here. here. of, at

So it's maybe of sort just help of us understand X% organic sort why midpoint. still at a the

us on that, a and help Just have few I educate follow-ups.

Frank Laukien

Yes, I in companies guidance the that pleased on be mean, we're this lowering are very tougher macro. to a among

So for weaker but more of other in that, areas year. gigahertz macro sure, uncertainty are sensitive don't more strengths highlights. those of NMR is feel microbiology, this you cited, some proteomics, our we the – have we're they are few comfortable the macro have with that there and markets disagree And a – become that I of the some others,

are in meaningfully And year. guidance So we and fact, we hit this whether track year. really on incrementally our probably, can we de-risked, think, guidance non-GAAP EPS we the have are for increasing

this seems that at time. prudent So

Puneet Souda

expectation gigahertz I asking your academic you specifically to I Okay, and and around guidance. customers thanks. you talked those if reflect XXXX what's not into of within touch, here, the and your how up us to update few And sort in But here Europe, the the in sense and here? what's X.X a and of of So gigahertz does know, a of the And if X.X there. then of could on we just the the X.X sort as field? give view if sort on us both of into go are could status you. that they're and I'm terms going And customers, quarters next couple the how you government Europe, as Thank could questions many of factory, NMRs? in

Frank Laukien

now at said in Gerald – there quarter-to-quarter, Europe about or me in you with revenue is we if bit maybe we first fluctuations, you look Europe take the probably it help first a trend in the feel revenue, as others. little last And I think there better over months? we'll if quarter, can nine over Europe Europe, say Europe than Okay. nine some maybe What's you Miroslava. had some for months the a

Miroslava Minkova

organic an It's up, obviously, on basis.

quarter up third The was digits. high-single

Frank Laukien

in Europe. then timsTOF microbiology and Yes, the orders high-single well is are well. well and and doing mean digits in Europe is as really doing up Europe, I

German are funding exposure of a Brexit funding Some I feel the has and really European slower. down a so-called also little we there, good. or but uncertainty the exposed But course, have earlier, our good not can slowed pretty in academic this we're think UK we and fraction with but microbiology I of And car little I and feel, on going are good, Europe. bit, is Europe vehicle industry quite academic heavily overall, said I know investment Europe. we're that industrial not which life over is in is quite to of maybe the and capture I really trends about science good strong funding is tools only as there

gigahertz, and Twitter, pretty So And than you as nine you bullish, come it we but one as I pretty may round, about gigahertz, much all more recall, we shipped good feel on a little to year X.X X.X as Europe we're have order and positive field. has has say some X.X we're heard in won’t gigahertz from said, others. – we have Europe.

guidance the So we that because quarter or our way, in else either doesn't first maybe may or revenue really something may it QX, accepted affect that not then into in have get so. if goes

milestone. And And that's that customer's NMR have in at and – generating X.X pipeline. these production anyway, of hybrid the news, X.X gigahertz had the another have have more shipped and been But we or system has the two first That's at we system field factory has come X.X data. to great site. little a field gigahertz

year, revenue hope show So the we gigahertz we February. to what discuss not can hope early that time first in X.X we're next I much giving but in up will extent guidance, for very XXXX

that, science has State system one piece national the X.X nice the that in at University. was foundation first an have – bit project large U.S. funding in for a we it institution an order. that maybe course news breaker of of the U.S. order ice is the Ohio federal will and And, gigahertz a but And for hope a funded potentially the is major a great States we don't U.S., more has very this funding that be received United nice

Puneet Souda

All right. Thank to you so Thank great you. much, hear. that's

Frank Laukien

Thank you, Puneet.

Operator

question And Bank from comes America our DeBruin of Derik of next Merrill Lynch. ahead. Please go

Derik DeBruin

afternoon. good Hi,

Frank Laukien

Derik. Hi,

Derik DeBruin

strong Hey, that you on? first what's Can commented you spectrometry. Europe in question about mass talk is, on rest life little lot been science a respect. U.S.? Also, has geographic the in world growth and in is going about of Bruker bit how market, or a a in your talk Thanks. And stronger I follow-up. of share America in North have still it change the market sort you is x and very Can that historically,

Frank Laukien

Yes.

growth pointed I seen think years to mass refresh Japan in what think four it from proteomics, out, we're or actually have we're we’re sure. last significant our also mean, the much nicely also in right pretty the we’re mass I can mean And share is in a given very momentum fields gaining there stronger of the for – spectrometry. three, in had world true biopharma, us nice applied looks geographies, of we’re mass metabolomic from already, phenomics. increasingly throughout And So in – I life really, rest whereas portfolio pharma, Derik, we’ve the I in some tell, and science most And China. – you've many that also spectrometry and now, Europe, but U.S. in so I or really in like we're that's growing

it’s and, for course, from And all proteomics, and looks the are that are positioned biologic cell ones. biopharma major single to of – but healthy the the opportunities trends of those and think some biology I others, we metabolomics so have around which ourselves

macro are These not that dependent.

as them, pharma good. non-profit this including non-profit as for in excellent funding funding, that’s Med including and also So well School academic is research. case There

on So catching it wants perhaps good not mean, discovery, the macro life a I significant that any Americas tools bit drug research will doing dependent, science up interested drivers, well, – where growth pretty Asia. be dependent and in not do little that somewhat and quite we’re to we’re country or in in the these geography,

Derik DeBruin

Great.

about Have Chinese there, the indicators Speaking back? the of talk you Asia, you’re obviously, can pull Chinese been R&D there seen in folding any and what spending? market have back we seeing

Gerald Herman

Derik, a it’s been year. Gerald. through Bookings story bit We us. would say, solid the I nine a and in has pretty generally, had that There’s China softer of than but patterns terms we delays. in months some QX China from first like, of see there’s for delays there – revenue that’s would little of I both just mixed few think partly just paperwork some a somewhat we part expected, orders, it’s softer order are generally.

but we it of if overall have talk business. far. China, the solid business overall. represents I tariffs, there about issue a know, don��t see we any XX% about And so I you in the it’s already pretty like, think I can think significant you’d

Frank Laukien

feel Especially there on letting China. I strong that to not that up China I a continued science push research and was Again, life is high-end funding, I generics. research just see research notch at top and September don’t exposed in in that the all. part funding we’re

including We’re Asia, nice as microbiology, China. growth as had in well we’ve doing fine in

We’re to exposed or small not pharma there that CROs. molecule

in a pace we last after year. So continues think good, a and very at the questions overall, maybe, NMR that growing weaker growth little pretty we the Overall, wonderful a you components good order and little growth, signals much. looks specific of were research get Many academic biopharma they bookings microbiology, slower high-end this revenue bit where research year than year. last funding China research areas

It’s remains I for think impression. a top priority that my China.

Derik DeBruin

Thank you.

Frank Laukien

welcome. You’re

Operator

ahead. next go will Doug our question from Please with And Cowen. come Schenkel

Chris Lin

I Chris on question. taking for with CALID. this for just want my to start Hey, is Thanks Doug.

growth So has CALID year to accelerated meaningfully this double digits.

a but I not in are dynamics. you think And think how there we you XXXX if do any mass I’m refresh terms analogy, were improvement what do curious use diagnostics new in if you guidance, growth. sustainable spec cycle? you growth think inning this in of and And looking the in, were to is? about baseball driving other talked portfolio placement instrument for

Frank Laukien

there So very capabilities. diagnostics, baseball a mass they That’s is spectrometry and we game MALDI great really for Biotyper in the it’s clinical have And a sure. and need well. more have Biotyper do always in more relatively solutions steady just market. MALDI and

clearance capabilities. We’re certain additional things perhaps by well. and more going the market in even there is large winning Hain are acquisition There of U.S. the for FDA share in pipeline

that’s a we’re low very teens there well of to continues the of grow business So part consumables business the that and is north sort and of the delighted to even steady XX%. back business instruments that

to final again, up I’m I will genomics I know, coming necessarily no XX, in big baseball we’re as where years solid no not very be no ago. there there. XX think as So with but don’t Proteomics, proteomics roughly in all. proteogenomics sight, inning saying total, end that analogy at

and is there. I are think these and more our technology becoming more appreciated markets healthy

metaphors to runway, games, So baseball these really these markets. don’t apply no no

Chris Lin

help Okay. guidance us bridge EPS And then Gerald, could the you year. just for the

to only on growth EPS year implied and rate meaningful QX increased full guidance XX.X% by a X%, beat is then $X.XX think you relative about QX which rate posted think I by is I slowdown the $X.XX. EPS basis. The you you year-to-date the

has nice some this clearly, been momentum year. there So

effort sure anything to guess, we’re not I guidance full derisk EPS updated an Just year. for guidance is, really missing want and here the make to

Gerald Herman

we’re guidance good on year into Well, And profitability over that, stage. posted we some very the posted perspective first provide EPS numbers months. the our is performance we Clearly, what nine this I’d should we’ve updated say clearly far. solid feel it from for generating the we full thus at of like I guess

we’re just I come So range the highlight it that performance. at in to margin helping I moment. reasonable to by being a there’s I don’t sure. continued drive moving is anything think our than operating And The to is driven for we really product think the expectation. special mix want other would more

Chris Lin

And – quickly question. sorry. just Okay, last last

had growth in that I know you think you strong Japan.

Japan that in not, forward to all? talked Does dynamic your of how is due added from If benefiting Thanks. of orders, that value tax. growth Some pull the Japan peers here. sustainable at you potentially increase impact about the a

Frank Laukien

Yes, any this be whether orders material estimate of a and revenue that or that for effect all. Keep in was us we partial on us to tends quarters a average. at would between allow couple don’t mind data about have to

change excellent We’re really third quarter in the very, But been so us, this comes aware trends growth on of year well Japan in the good very with really many for not of VAT row us, has but for in growth. a has weak demand pent also least. some The very Bruker, up that in for not probably really performed it for Japan. years in year-to-date, and is sustainable. top Japan just at general,

any to we So delightful very year Japan it’s of us but estimate on color a also we’re aware Japan. and is for little data of way. bit but allows been have the and up. us not change, VAT don’t That’s material, doubt in it’s all year this that catch that that any the has we’re we –

Chris Lin

All right. for questions. taking Thanks my

Frank Laukien

Sure.

Operator

question And go Dan come of the ahead. UBS. from next Please Brennan will

Dan Brennan

for I digging like in you. just about kind about quarter. the when Frank, take quarter X% little wanted macro, guide, it X% to cushion fourth the But some more in your Thanks guess. questions. you’re obviously, it’s of just bit understand thank for to uncertain Great, guide, I taking the fourth you looks a

it a get or So within I’m now year-to-date Is business, X%, little which wondering, you even to a to number about range. just like the you maybe kind but full end year give very number. me or more low the of pointing weak excuse could color, semi to the you’re talked

of of going down the to the get seems what just of follow-up range, that X%. we bottom Thanks. it kind half have a you to range? Because well. that hard of of certainly is kind to crux of X% bottom to the would the of as kind kind So to I’m get

Frank Laukien

giving guidance. I fourth here quarter mean, we’re but not in a be my we’ll a bit of stickler then case,

our updating full guidance. year We’re

We’re we’re to track our delighted that full much year very deliver on guidance.

quarter strongest wouldn’t strong. need I would to strong fourth was of very the too quarter, – as to year. much – it. last in a And as We quarter year every we deliver very read have of We always into fourth need year a will

for the and a very to pleased in delivering full on guidance be We’re environment. track year weakening

job all I’m to So and say I that. we’re going our that’s this about year think doing

Dan Brennan

– a only market but you that just the quarter. really opportunity not kind Okay. the a And to you boxes, grow that a kind had advances you maybe the see then place had also Can strong the know on of us and box to felt obviously, you are timsTOF, real given delivered. I market? looks like nice did just of update penetrating where you you

color kind business we just base think terms you us of going your of can update sizing that So about today of the and in how forward? kind give any of of

Frank Laukien

maybe meeting about biology, many that, the of we you driver benefit use market how from events. the pharma of the an bore good overall, there’s International major lot all as proteomics but won’t proteomics. clinical them, a but inflection HUPO a with continue good. It to I single many at of so inch positive which Yes, there cell of to very in showed that us, know, really growth you others Australia confluence to in field proteomics, not was other will point the only Dan, feel in with applications. And

where make on it. is and it’s well attributes an doing very very performing, bullish a can it certain I’m So, and It In unique it Pro; general very timsTOF additional robust high we’re an the area, capability. yet, you has that with proteomics. compare clearly

established. welcome very and starts addition it a be now the years really launch, it’s So, to quite two after

who technology, one. but it everybody’s having now explain heard maybe someone We’re brand-new has not about to

opinion really we’re And very leaders key we’re still of to launch – so paying costumers going is still the of that and well. of S-curve. lot the and the all we’re attention in part early that And early a in

now I I’m a but long it’s pretty another S-curve worried. think for not metaphor, And proteomics, use so so

part, still that’s then early right it’s rewarding. little but to a in and beginning bit accelerate We’re the

technology has really mean qualitative field viable the this the reception of received. very, enthusiastic reception, been, almost and the you think capable very I I and that’s having an in additional technology

Dan Brennan

Great.

Okay. and much congrats. Thanks very

Frank Laukien

Thank you.

Operator

go from ahead. question Please Steve Cleveland Our of next will come Research. Willoughby

Steve Willoughby

evening, Most just business. want I but to asked, taking the follow of and questions. BioSpin for my on Frank, been have thanks Good back them up

bit little seeing, So, if I you BioSpin also business questions. could what about about the the going you’re in guess and talk forward, in quarter a I guess two

quarter First, the was you grew the one in here by aided low-single and system that digits gigahertz you sold. that obviously

the And So, systems of kind could NMR potentially pipeline also, year? about could if bit little going talk about underlying for market? you a BioSpin on you then us on what’s maybe, provide look refresher a like just next the gigahertz what reminder for

Frank Laukien

Steve, sure.

– think organic was made a in we’re We QX elsewhere, not digit we it underwhelming. performance strong but full BioSpin’s a BioSpin why said the remarks, performance. I prepared year; my during it was little the BioSpin. up that for So, expecting And that’s still growth mid-single that’s for

all was Something than and, a less was we’ve – year but however said QX little that.

think I appears your out QX BioSpin you’ve and some the some negotiation year. for for and think have have some we pointed strongest under But and the U.S. additional BioSpin. there and you’ve for with are funding systems. the right is to all in for ultra-high and So, will fields we question, mean not pointed for there’s as was be be a will there I decent QX – years backlog elsewhere, funding multiple now

roughly a because start we that to over people But it. may new years. our we so we are So, the expect delivering, and or the deliver be that down three we’re we what quoting now, years encouraging looks deplete we funding, little long, to it I’m necessarily four pipeline bit, multiple once times pipeline will I or our backlog pipeline mean, of delivery very right we not for convinced what the of that looking should in have able terms replenish more. but to have come already

of a guidance timing the not let year, to that experience but likely some February what it give that you add to the to is give revenue we from ever, in to then pipeline. deliver us a over hope for that going the get a ramp first a little gigahertz bit time well years will technology I’m X.X be contribute The backlogs with with feel that, next multiple we’re the X.X of have we for have that and as hopefully, year we and and But we hope time be – next get right as that then XXXX. course, but our expecting to of will for there to reasonable we component still XXXX gigahertz hopefully, uncertain, when for

Steve Willoughby

quarter. remarks, follow-up. and I expect if digits about the don’t Frank, which commented you mind, could a comment you quick in fourth continue you growth grew Okay. to prepared that specifically one your business, if high-single have the don’t that In made NANO you

the better You which of that just that double-digit question growth just low-teens, expected CALID I the going you fourth it of kind I keep kind Can growing kind was CALID, in Dan’s there I’m BioSpin of rate? back regarding organically in quarter. in the made get believe at a quarter to; terms implying guidance. quarter comment fourth then believe to of and grew

Frank Laukien

much the have way it, We’ll said correct growth asked is the about groups all some growing it remember of at similar ago, Steve, Yes. at of we actually rates. more you it as That’s rates. time or all had diversity

is place rates, that CALID even than year that out. is all that’s the organic be best play And this weigh really with likely fully to seems nicely digits. better having expected. and it’s BioSpin And or growth going this had to maybe, likely picked how the itself high-single So, we in year low-teens up mid-single and digits, to in very for NANO low-single digits so.

bit a BEST about as weaker and the a and So, beginning stronger, stronger NANO at year than CALID a we of had the bit expected, like BioSpin expected bit than expected.

year we go see what in we XXXX So new XXXX, that’s the the call let’s how February. as into but picture them for predict we

Steve Willoughby

so appreciate Okay. it. much, Thanks I Frank.

Frank Laukien

Sure.

Operator

And our Please go & Needham Company. Unger of ahead. next Steve question will from come

Steve Unger

Thanks. guys. Happy Halloween,

Frank Laukien

Thank you.

Gerald Herman

you. Thank

Steve Unger

right. All

the base into Biotyper into is as the little that and – complimentary the question, upgrade you base? performance should a consumable or how bit microbiology a we system and As could as, far placements just as far my think sale versus about into the first sirius an new maybe, dive growth touch on further

Frank Laukien

or leased. free for Right. Microbiology here it’s solid in any for our model. are We today. us, really don’t growth really business Placements place sold units

double-digit to digit. a are globally I couple have MALDI units for was So, Biotyper the It back like growth years. do more been high-single to think of

Europe strength, but a little that particularly, really weaker do that’s So in in A the with. U.S., and to have bit in delight Asia. may

get we in We’re might clearance with waiting this maybe winter, the here contact claim to in whatever steps additional clinical we’re and that the FDA trials type means, with U.S. in an FDA – our and FDA for the clearance sometime

we be consumable really the XX%. – that’s now to point, only software may as higher, continues continue as aftermarket recall, will XX%, after we’ll and That’s in faster sell we than you systems probably more service the market. trend that than business So be, consumables saw at fantastic already, and growing XX% we some microbiology

new sirius yes. introduced Microbiology. The system, nice got then We the since Society We of capabilities. also at CEIVD American

through still and it into, not go go all some unregulated in that countries, ship can now can to only we countries, So, in markets. regulatory has into

It’s – the regulated most So with laser system It’s the that usual and not the high-end, robustness is MALDI customers generation so And also high-performance really a shots, increased lifetime next for powerful. there’s laser more things complimentary. most when Biotyper. on. deal you and some

It competitively. some So, in in U.S. Europe cases, very allows newer later. usually of first, approved that only us are it’s help a methods are research-use should already or compelling It offer. in these some

it’s And so as going Biotyper have the it’s smart to and the – MBT, solutions. of MALDI affordable high-end classic sort be the more we’ll it’s and

than – but sirius, heard sirius forward a for want is everybody them. a the very to me, that’s that product proof I what they’ve future can then So, of a proposition the And people have sirius, good to range rather this value excuse word, not need will a afford product. line bit we single proof, if very, probably in

Steve Unger

an in then you’ve Malaysia the impact color. you And complete can on about of that to fully see will and just we the be And when as transition noticed that was curious and Great. to comment quarter I involved. good restructuring That’s reversed impact very charge maybe I the start capital? what could working

Frank Laukien

Okay.

heads So, our a we’re bit. little scratching

gain catch. good was there restructuring a think was one facility that there indeed, gain Yes life business. of of our Bruker sick, I on detection the a Wow. in a part was on facility so

at So, facility. we of the as leased then restructuring a earlier part back that had We we and some that, of sold end a charges taken have other gain. and only

products So the isn’t go by will not as that of that’s the that year. more done item. Penang, up ramp up end actually, Penang, to the ramp will the – be

that be products the – So, some any products then from product Penang, there’ll will move some facility. additional for come to some normal that but be they

year products I maybe, other me that it’s in that February. than moved takes much – multiyear a a just that every into you the products, one of have don’t ramp-up year we of, So it facility. right I but don’t sort of bunch let for you a get now. answer it’s a But have better additional say clear moved answer to a and

Steve Unger

it. Thanks. Great. Got

Frank Laukien

Yes.

You’re welcome, Steve.

Operator

will Sung BTIG. Ji Please of ahead. Nam our come question from go next

Sung Ji Nam

about Thanks legacy of quick just one Frank, talked placement you you system taking this could the – for Hi. gigahertz maybe, couple a about your ones, talk pricing the quarter. affecting questions.

situation quite anticipate one-off or we that what not like a that’s in if the pipeline? systems other sure and the could wondering, or is was like Just that of some

Frank Laukien

development almost got or Agilent. key that XXX think really a XXX later in that or nine then varian, for is to site eight ago. later was one situation system, was We a funded on ago years that’s be one-off that NMR a It a was years gigahertz – system No. renegotiated as a originally or ago maybe megahertz decade

many it – the very And almost order with boring It’s got, customer. So, this is negotiations very, decade. but old a really you part a better the on – of as very, competitive one-off. all has old it an gone details. was the case. for and wonderful that years It a for and not it my very is It’s order old is

one-off. So, it’s

Sung Ji Nam

lot good quickly, there geographies? are the share growth, taking just seeing data then market you across of to obviously, growth a microbiology, and And the different Okay. on as well

Frank Laukien

on MALDI from the preferring ID are the launched, now ago, business, decade statistics the we’ll sirius. customers, from and color, from ago seven, we or have the clearly company some have don’t are purchased really that, some data – a today have maybe, who that system Probably, products some of eight Biotyper we they of we get we, them have probably, including smart or – platform years newer and from we other but customers, MALDI the the another the

little that our we So, data we in probably market a bit gaining is but have sense to as well. prove – share don’t it, we’re

Sung Ji Nam

you. Thank Great.

Operator

Please come will ahead. Evercore of from Kumar question next Our Vijay go ISI.

Vijay Kumar

congrats came QX, maybe, QX guidance. above the little you nice sprint on this question it easier. Frank, the guys. Clearly, look on a – comps here. well a at gets Hey, in QX

aren’t coming worsening, it’s it’s easier It’s to according in not back, industrials to but comps your Given expectations. the Why expectations. that according playing wouldn’t QX guys? help comments you

Frank Laukien

and good hinted that QX the sets new this I we derisk good before, had Well, a we derisk the on QX had saying QX is guidance on above but year. to and average our full-year the right? to standards not quarter we’re and mean, as expectations, another good was for quarter focus it probably little bit a QX. guidance. we’ve We focus – year, a

We’re raising it a bit. little

growth clearly points. just tight you pretty Maybe, little being We’re could you pretty say a data industry year, spread the you but had what between, of it lot industry; a cautious, is, last a was. the bit get

if hard last seen we’ve it I a that’s you points data which right to you take mass XX spread life say points think reported or days that whatever this spectrometry, pretty or of in science look data quite that’s at now, tools the actually is.

Journal, read – confident bit we little right? we’re this slightly year can more Wall Europe – I you’re very feel think we this the and raised at with increasingly a our we’ve we’re that for So, and cautious, think that. is I Street pretty deliver and you it’s the simple. And But look you guidance comfortable

Vijay Kumar

core, didn't one a came little contribution margin curious that guidance implies, is which investment down of which And looks in the where enough. coming fair going? slightly like on bit, investing that given I’m Thank means, business. quick than you. FX just you That’s the one expected, It the margins. in change is better

Frank Laukien

good Very that’s catchy, exactly right.

for to pleased year. headwind improvement solving little we’re our We’re we’re there. on margin get reported each That’s bit a than And track job. more FX

and course, large. of more. Accelerate there, out or did little single could into wouldn’t goes by many of other one goes And them. the initiatives we that a And Project invest really into indeed, that’s, our and bit So I

So that’s a doing. very astute what exactly and we’re that’s observation

go not to we’re bottom all letting So, that the line.

have. We’re sure actually that not be we pleased able some to of to and underinvest invest make the in opportunities that don’t we

Vijay Kumar

Frank. Thanks,

Operator

will question from go Tycho come Please next of Peterson ahead. JPMorgan. Our

Tycho Peterson

Thanks following when cash that online about potential for separately, and expansion could for here think talk coming then margin you operating facility that Can a to Gerald, just well. as you on free you start that, turn? flow how you guess the up Malaysia we just facility, talk we I as Gerald, me can should little a margin, for bit, think on fitting just about on think the in. about

Gerald Herman

the activities them. growth comment I Malaysia, looks into to we business drive would about in production further our I is XXXX, tell in of that’s – to CapEx Penang of talk into generally, that that year. me that let of forward intended Well, place. going and I’m meaning broader Malaysia just are operational excellence the full other on we And program. put is Sure. it part for part will the say baked but one how all look program you as a There’s that’s a of not number guidance production that

you in did – in flow, some largely by driven the cash that the and softer me talk of transition flow we time into free inventory activities I first know, of think Penang, we free cash on bit nine probably our flow, cash free time months. from about let in little That’s do a just buildup maybe, the generation respective to slightly with fluctuates products lumpiness the see, if that Malaysia. briefly, of have

bit well, for inventory In addition, we capEx little our have for you a addition, know of we systems to buildup have NMR. gigahertz probably in in increase of XXXX. as and the relative some

some finally, would I impacted also that. timing, say shipment is just

you it QX don’t I a generally know, So, I cash planned, very – as of we revenue, large flow. have a probably and lot generates margin, operating mean

full will So, quite we for cash free about we’re still flow. on land how optimistic the year

Frank Laukien

gradually of operating And tax being term, margin is beyond Malaysia one also for of Malaysia beyond medium Tycho, it important elements plans improve expansion. the ongoing to our our further – effective our rate.

Tycho Peterson

contribute ASMS expand before Frank fleX on the the And you – was here just at it the is of the back part starting once on then spatial on Pro, the tim. and can timsTOF year? strategy timsTOF half to MALDI, in to of that question comment

Frank Laukien

Yes, a little, of is than market contribute. I much a – market. it’s – that’s it’s mean more timsTOF that’s much but smaller platform beginning – of overall. proteomics it a part overall to it’s smaller the a but

Tycho Peterson

then, go then ahead. And right. well, just All last one one

Gerald Herman

ASMS and a before take so received, while well expensive system. So, as these – yes, people we did that’s a it’s receive more going have expected, orders – since things it’s it’s

up, budget. budget, something, where show it bigger spend I hey, simply a on need to would have going people you a So, is instead. you not I’m This

of at all It’ll of market. not proteomics the half smaller a a sudden niche. a that, launched third this given So, it’s even long-term, it but we or well, be timsTOF will going ASMS, be just the

Tycho Peterson

And you outside of do starts in the is Ohio had state. a Asia see flag to have? kind next on you up Europe? and then the much year U.S. the or think, to lot How I think it NSF appreciate questions of to longer of starting at NMR. funding I the initiative incubate you’ve funnel, pick of Do you

Frank Laukien

Asia. some still Europe have U.S. to – but to in in expected the it’s is and Yes. is expected that that be also indications, active, we We the indications of more funnel but hope we some be in have yes,

correct but I to Europe’s only done a make. yet that’s observation, point either, the So not it’s wanted

Europe potential expecting as additional So, funding we’re well. a in

Tycho Peterson

Thank Okay. you.

Operator

conference question-and-answer for session. like over remarks. back Minkova I turn our concludes This to go to closing ahead. the please Miroslava any would

Miroslava Minkova

XXXX various in fiscal us the Stifel quarter, Jefferies London the during York, and joining in Conference updating QX in Thank JPMorgan you call the Conference In look Healthcare course us we New San conference meantime, healthcare events Healthcare again, our of you XXXX. on forward investor in including conference invite for the to the you today. meet over Francisco. London February the year We to early

You’re visit have and evening. Billerica, you also Massachusetts. a our in good welcome headquarters to Thank

Operator

now The concluded. conference has for Thank today’s you attending presentation.

now You may disconnect.

Bruker (BRKR) 31 Oct 192019 Q3 Earnings call transcript